Mode
Text Size
Log in / Sign up

Individualized dosing strategies optimize therapeutic efficacy and minimize toxicity compared to traditional weight-based dosingPrecision dosing may improve safety and results for critical medications

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider individualized dosing to optimize efficacy and reduce toxicity compared to traditional weight-based methods.

This narrative review explores the clinical utility of individualized dosing strategies, such as PK/PD-guided strategies, model-informed precision dosing (MIPD), Bayesian adaptive dosing, and biomarker-guided dosing. These methods are compared against traditional dosing methods based on weight and body surface area.

The authors synthesize evidence suggesting that individualized dosing optimizes therapeutic efficacy while minimizing toxicity through patient-specific dose selection. These advancements are intended to support a shift toward more precise, evidence-based, and patient-centered medication management.

Several limitations are noted regarding the implementation of these strategies, including dose calculation complexity, potential for medication errors, and various operational constraints. The review does not provide primary clinical trial data or specific adverse event rates.

For clinical practice, these findings suggest that precision-dosing strategies may offer a more tailored approach to medication administration. However, the practical application is currently constrained by the complexity of the calculations and the resources required for implementation.

How this fits prior evidence

This narrative review addresses a gap in the transition toward precision medicine. It complements the finding that precision oncology and biomarker-driven strategies enable personalized management of prostate cancer by providing a broader framework for individualized dosing across various medication types. While the review does not provide specific trial data, it supports the shift toward precision-based care mentioned in other contexts.

When a patient is seriously ill, the right dose of medicine is a delicate balance. Doctors often use standard formulas based on weight or body surface area to decide how much medicine to give. However, these standard methods do not account for every unique factor in a person's body, which can lead to treatments that are less effective or more toxic than necessary.

Newer strategies, known as individualized dosing, aim to change this. These methods use specific data, such as a patient's unique biomarkers or real-time modeling, to pick the best dose. This approach is being looked at for several types of high-stakes treatments, including chemotherapy, immunotherapies, and medications used in critical care. The goal is to maximize the medicine's ability to heal while minimizing the harm it causes to the body.

While these precision methods offer a more patient-centered way to treat illness, they are not perfect. They can be complex to calculate and may face practical hurdles in a busy hospital setting. Because this review summarizes existing knowledge rather than new trial data, the full impact of these methods in every clinical situation is still being explored.

What this means for you:
Tailoring drug doses to a patient's specific biology can improve treatment success and reduce harmful side effects.

Common questions

What is individualized dosing?

Individualized dosing means choosing a medication amount based on a patient's specific biology rather than a standard weight-based formula. This includes methods like biomarker-guided dosing or model-informed precision dosing. The goal is to make the treatment more effective for that specific person while reducing the risk of toxicity.

What types of medications can be given with precision dosing?

These tailored dosing strategies are being explored for several types of high-stakes treatments. This includes chemotherapy, immunotherapies, antimicrobial agents, and medications used in critical care or under anesthesia.

What are the challenges of using personalized dosing?

While these methods aim for better results, they can be difficult to implement. Some challenges include the complexity of the calculations, the potential for medication errors, and various operational constraints within a medical facility.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
Individualized dosing has become a cornerstone of precision medicine by optimizing therapeutic efficacy while minimizing toxicity through patient-specific dose selection. Traditional approaches, including weight- and body surface area–based dosing, remain fundamental for many medications but are increasingly complemented by pharmacokinetic/pharmacodynamic (PK/PD)-guided strategies and model-informed precision dosing (MIPD). This narrative review summarizes current evidence on individualized dosing across four major therapeutic classes: antimicrobial agents, chemotherapy, monoclonal antibodies and immunotherapies, and anesthetic and critical care agents. It highlights the rationale, advantages, and limitations of conventional dosing approaches while discussing the growing adoption of fixed dosing for selected biologics with predictable pharmacokinetics. The review also examines practical challenges associated with individualized dosing, including dose calculation complexity, medication errors, and operational constraints. Finally, emerging precision-dosing strategies, particularly Bayesian adaptive dosing and biomarker-guided dosing, are discussed as promising approaches to further personalize pharmacotherapy. Collectively, these advances support a shift toward more precise, evidence-based, and patient-centered medication dosing.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.